News Guardant Health, Inc.

Equities

GH

US40131M1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
18.1 ^USD	+4.38%		+12.00%	-33.09%

Apr. 22	Sector Update: Health Care Stocks Increase Late Afternoon	MT
Apr. 22	Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Advisory Panel Review of Guardant Health's Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23	Apr. 23	AQ
Sector Update: Health Care Stocks Increase Late Afternoon	Apr. 22	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 22	MT
Guardant Health Says FDA Advisory Panel Will Review Shield Blood Test for Colorectal Cancer Screening; Shares Rise	Apr. 22	MT
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23	Apr. 22	BU
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024	Apr. 18	BU
Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	Apr. 15	MT
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	Apr. 03	BU
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	Apr. 03	CI
Guardant Health - Royal Marsden And Guardant Health Partnership Provides State-of-the-art Blood Test To Benefit Lung Cancer Patients In Expanded NHS Study	Mar. 25	AQ
Blood test shows 83% accuracy for detecting colorectal cancer in trial	Mar. 13	AQ
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine	Mar. 13	BU
Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer	Mar. 13	CI
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 06	BU
Guardant Health, Inc. - New Survey, Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap	Mar. 04	AQ
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap	Mar. 01	BU
Transcript : Guardant Health, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 01:00 PM	Feb. 29
Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating	Feb. 26	MT
UBS Adjusts Guardant Health Price Target to $32 From $45, Maintains Buy Rating	Feb. 23	MT
Canaccord Genuity Adjusts Price Target on Guardant Health to $45 From $50, Maintains Buy Rating	Feb. 23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Guardant Health, Inc.

Equities

GH

US40131M1099

Summary

Filters